Research programme: alpha-2B adrenoceptor antagonists - Juvantia Pharma

Drug Profile

Research programme: alpha-2B adrenoceptor antagonists - Juvantia Pharma

Alternative Names: Alpha-2B adrenoceptor antagonists research programme - Juvantia Pharma

Latest Information Update: 18 Feb 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Juvantia Pharma
  • Class
  • Mechanism of Action Alpha 2b adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Vascular disorders

Most Recent Events

  • 20 Jul 2005 This programme is still in active development - (BIO-2005)
  • 31 Jan 2001 New profile
  • 31 Jan 2001 Preclinical development for Vascular disorders in Finland (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top